Cargando…

Muscle NAD(+) depletion and Serpina3n as molecular determinants of murine cancer cachexia—the effects of blocking myostatin and activins

OBJECTIVE: Cancer cachexia and muscle loss are associated with increased morbidity and mortality. In preclinical animal models, blocking activin receptor (ACVR) ligands has improved survival and prevented muscle wasting in cancer cachexia without an effect on tumour growth. However, the underlying m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hulmi, J.J., Penna, F., Pöllänen, N., Nissinen, T.A., Hentilä, J., Euro, L., Lautaoja, J.H., Ballarò, R., Soliymani, R., Baumann, M., Ritvos, O., Pirinen, E., Lalowski, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364159/ https://www.ncbi.nlm.nih.gov/pubmed/32599075 http://dx.doi.org/10.1016/j.molmet.2020.101046

Ejemplares similares

Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses
por: Nissinen, Tuuli A., et al.
Publicado: (2018)

Blocking Activin Receptor Ligands Is Not Sufficient to Rescue Cancer-Associated Gut Microbiota—A Role for Gut Microbial Flagellin in Colorectal Cancer and Cachexia?
por: Pekkala, Satu, et al.
Publicado: (2019)

NAD(+) repletion with niacin counteracts cancer cachexia
por: Beltrà, Marc, et al.
Publicado: (2023)

Activin Receptor Ligand Blocking and Cancer Have Distinct Effects on Protein and Redox Homeostasis in Skeletal Muscle and Liver
por: Hentilä, Jaakko, et al.
Publicado: (2019)

Differentiation of Murine C2C12 Myoblasts Strongly Reduces the Effects of Myostatin on Intracellular Signaling
por: Lautaoja, Juulia H., et al.
Publicado: (2020)

Prevention of chemotherapy‐induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle
por: Hulmi, Juha J., et al.
Publicado: (2017)

Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments
por: Hulmi, Juha J., et al.
Publicado: (2021)

Inhibition of Activin/Myostatin signalling induces skeletal muscle hypertrophy but impairs mouse testicular development
por: Vaughan, Danielle, et al.
Publicado: (2020)

A muscle growth-promoting treatment based on the attenuation of activin/myostatin signalling results in long-term testicular abnormalities
por: Vaughan, Danielle, et al.
Publicado: (2021)

Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling
por: Alyodawi, Khalid, et al.
Publicado: (2019)

Mitochondrial Dysfunction in Cancer Cachexia: Impact on Muscle Health and Regeneration
por: Beltrà, Marc, et al.
Publicado: (2021)

Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy
por: Puolakkainen, Tero, et al.
Publicado: (2017)

Myostatin/Activin-A Signaling in the Vessel Wall and Vascular Calcification
por: Esposito, Pasquale, et al.
Publicado: (2021)

The Skeletal Muscle as an Active Player Against Cancer Cachexia
por: Penna, Fabio, et al.
Publicado: (2019)

Moderate Exercise Improves Experimental Cancer Cachexia by Modulating the Redox Homeostasis
por: Ballarò, Riccardo, et al.
Publicado: (2019)

Upregulation of activin-B and follistatin in pulmonary fibrosis – a translational study using human biopsies and a specific inhibitor in mouse fibrosis models
por: Myllärniemi, Marjukka, et al.
Publicado: (2014)

Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
por: Rodgers, Buel D, et al.
Publicado: (2021)

Myostatin is a novel tumoral factor that induces cancer cachexia
por: Lokireddy, Sudarsanareddy, et al.
Publicado: (2012)

Myostatin is a novel tumoral factor that induces cancer cachexia
por: Lokireddy, Sudarsanareddy, et al.
Publicado: (2016)

Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone
por: Iskenderian, Andrea, et al.
Publicado: (2018)

Myostatin Levels and the Risk of Myopenia and Rheumatoid Cachexia in Women with Rheumatoid Arthritis
por: Gonzalez-Ponce, Fabiola, et al.
Publicado: (2022)

Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes
por: Nissinen, T. A., et al.
Publicado: (2016)

The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy
por: Zhong, Xiaoling, et al.
Publicado: (2019)

Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight
por: Lee, Se-Jin, et al.
Publicado: (2020)

Activin/myostatin receptor signaling and vascular calcifications in chronic kidney disease: A “liaison dangereuse”?
por: Garibotto, Giacomo, et al.
Publicado: (2019)

Whole‐Body Metabolism and the Musculoskeletal Impacts of Targeting Activin A and Myostatin in Severe Osteogenesis Imperfecta
por: Omosule, Catherine L., et al.
Publicado: (2023)

Inhibition of activin-like kinase 4/5 attenuates cancer cachexia associated muscle wasting
por: Levolger, S., et al.
Publicado: (2019)

Estrogen regulates muscle bioenergetic signaling
por: Laakkonen, Eija K., et al.
Publicado: (2018)

Activin-β(C) modulates cachexia by repressing the ubiquitin-proteasome and autophagic degradation pathways
por: Marino, Francesco Elia, et al.
Publicado: (2015)

New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration
por: Pasteuning-Vuhman, Svitlana, et al.
Publicado: (2017)

Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A
por: Lee, Se-Jin, et al.
Publicado: (2020)

p21-Activated Kinase 1 Is Permissive for the Skeletal Muscle Hypertrophy Induced by Myostatin Inhibition
por: Barbé, Caroline, et al.
Publicado: (2021)

Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model
por: Hanada, Kako, et al.
Publicado: (2022)

Treatment with Soluble Activin Receptor Type IIB Alters Metabolic Response in Chemotherapy-Induced Cachexia
por: O’Connell, Thomas M., et al.
Publicado: (2019)

Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling
por: Xu, Pauline C., et al.
Publicado: (2022)

Activin A Plays a Critical Role in Adipose Tissue Wasting in the Progression of Cancer Cachexia
por: Luan, Yi, et al.
Publicado: (2021)

Pancreatic Ductal Adenocarcinoma Highly Expresses Activin A: Implications in Adipose Tissue and Cancer Cachexia
por: Xu, Pauline, et al.
Publicado: (2021)

Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin
por: Zhong, Xiaoling, et al.
Publicado: (2022)

SERPINA2 Is a Novel Gene with a Divergent Function from SERPINA1
por: Marques, Patrícia Isabel, et al.
Publicado: (2013)

Targeting Mitochondria by SS-31 Ameliorates the Whole Body Energy Status in Cancer- and Chemotherapy-Induced Cachexia
por: Ballarò, Riccardo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0jpftutec4e307nd6lq0p3g3g0